Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Small Cell Lung Carcinoma 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × DOXO-EMCH × Thoracic × Clear all
NCT03574649 2025-02-21

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02200757 2024-06-25

Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer

ImmunityBio, Inc.

Phase 2 Completed
135 enrolled 11 charts
Thoracic

Small Cell Lung Carcinoma

NCT00472771 2012-02-09

INNO-206 in Patients With Small Cell Lung Cancer (SCLC)

CytRx

Phase 2 Withdrawn
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡